Are Analysts Bullish about Vical Incorporated (NASDAQ:VICL) after last week?

October 13, 2017 - By Darrin Black

 Are Analysts Bullish about Vical Incorporated (NASDAQ:VICL) after last week?

Vical Incorporated (NASDAQ:VICL) Ratings Coverage

Among 2 analysts covering Vical (NASDAQ:VICL), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vical had 4 analyst reports since July 19, 2016 according to SRatingsIntel. H.C. Wainwright maintained the stock with “Buy” rating in Wednesday, August 9 report. The firm has “Buy” rating by H.C. Wainwright given on Monday, June 12. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, July 19. The firm earned “Buy” rating on Monday, June 12 by Rodman \u0026 Renshaw. Below is a list of Vical Incorporated (NASDAQ:VICL) latest ratings and price target changes.

09/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $9.0000 Maintain
12/06/2017 Broker: H.C. Wainwright Rating: Buy New Target: $9.0000 Maintain
12/06/2017 Broker: Rodman \u0026 Renshaw Rating: Buy New Target: $9 Reinitiate

About 112,809 shares traded. Vical Incorporated (NASDAQ:VICL) has declined 38.65% since October 13, 2016 and is downtrending. It has underperformed by 55.35% the S&P500.

Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid delivery technologies for the prevention and treatment of life-threatening diseases. The company has market cap of $32.15 million.

More important recent Vical Incorporated (NASDAQ:VICL) news were published by: Globenewswire.com which released: “Vical Announces that its Antifungal VL-2397 is Eligible for Limited Use …” on October 02, 2017, also Globenewswire.com published article titled: “Vical to Present at IDWeek and the 8th Trends in Medical Mycology Conferences”, Benzinga.com published: “18 Stocks Moving In Tuesday’s Pre-Market Session” on October 03, 2017. More interesting news about Vical Incorporated (NASDAQ:VICL) was released by: Globenewswire.com and their article: “Vical Announces Completion of the Phase 3 ASP0113 CMV Vaccine Trial” with publication date: October 10, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.